Expanded shareholder base by 13.5% and improved net result to -4.8 MSEK in 2025. Portfolio remained diversified with 62% unlisted holdings, and a new valuation principle led to a one-time negative effect. The local market was challenging, especially for Life Science.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.